Sandler Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Sandler Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-87,000	Closed	-$7.88M	–	171
2019 Q1	$7.88M	Buy	+87,000	New	+$7.4M	0.61%	70
2018 Q1	–	Sell	-65,000	Closed	-$5.52M	–	163
2017 Q4	$5.52M	Buy	+65,000	New	+$5.45M	0.78%	50
2017 Q3	–	Sell	-48,800	Closed	-$3.77M	–	164
2017 Q2	$3.77M	Sell	48,800 -111,200	-70%	-$7.89M	0.41%	88
2017 Q1	$11.1M	Buy	+160,000	New	+$10.7M	0.76%	34
2016 Q4	–	Sell	-134,800	Closed	-$8.94M	–	185
2016 Q3	$8.94M	Sell	134,800 -70,200	-34%	-$4.34M	1.1%	38
2016 Q2	$11.1M	Buy	+205,000	New	+$11.2M	1.46%	26
2015 Q1	–	Sell	-130,800	Closed	-$8.13M	–	257
2014 Q4	$8.13M	Sell	130,800 -45,351	-26%	-$2.59M	0.43%	82
2014 Q3	$9.16M	Sell	176,151 -221,049	-56%	-$11.3M	0.43%	95
2014 Q2	$20.4M	Buy	+397,200	New	+$17.9M	0.85%	31

Other funds holding XBI

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Sandler Capital Management's XBI Position: Q2 2019 in Review

Sandler Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2019, closing a stake of 87,000 shares — an estimated $7.88M sold.

Sandler Capital Management first reported a position in XBI in Q2 2014 and held it in 9 quarters. The position peaked at $20.4M in Q2 2014. 424 funds tracked by Wall St. Rank hold XBI as of Q2 2019.

Sandler Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2019 after selling out during the quarter.
Sandler Capital Management sold 87,000 State Street SPDR S&P Biotech ETF shares in Q2 2019, an estimated $7.88M.
Sandler Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2014 and held it in 9 quarters.
Sandler Capital Management's State Street SPDR S&P Biotech ETF position peaked at $20.4M in Q2 2014.
424 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2019.

Based on Sandler Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.